2
|
Wu R, Chen H, Chang N, Xu Y, Jiao J, Zhang H. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications. Chemistry 2019; 26:1166-1195. [PMID: 31479550 DOI: 10.1002/chem.201903128] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 09/01/2019] [Indexed: 12/14/2022]
Abstract
Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's disease, and cancer. This comprehensive account summarizes the recent progress (2014-present) in the development of bryostatins, including their total synthesis and biomedical applications. An emphasis is placed on the discussion of bryostatin 1, the most-studied analogue to date. This review highlights the synthetic and biological challenges of bryostatins and provides an outlook on their future development.
Collapse
Affiliation(s)
- Rongzhen Wu
- Department of Chemistry, Southern University of Science and Technology of China, Shenzhen, 518055, P. R. China
| | - Hongyu Chen
- Department of Biology, Southern University of Science and Technology of China, Shenzhen, 518055, P. R. China
| | - Ninghui Chang
- Department of Chemistry, School of Science, Northwestern Polytechnical University, Xi'an, 710072, P. R. China
| | - Yuzhi Xu
- School of Materials Science and Engineering, South China University of Technology, Guangzhou, 510006, P. R. China
| | - Jiao Jiao
- Department of Chemistry, School of Science, Xi'an Key Laboratory of Sustainable Energy Materials Chemistry, Xi'an Jiaotong University, Xi'an, 710049, P. R. China
| | - Hailong Zhang
- School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, P. R. China
| |
Collapse
|
3
|
Itoh H, Inoue M. Comprehensive Structure–Activity Relationship Studies of Macrocyclic Natural Products Enabled by Their Total Syntheses. Chem Rev 2019; 119:10002-10031. [DOI: 10.1021/acs.chemrev.9b00063] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Hiroaki Itoh
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Masayuki Inoue
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
4
|
Cummins TJ, Kedei N, Czikora A, Lewin NE, Kirk S, Petersen ME, McGowan KM, Chen JQ, Luo X, Johnson RC, Ravichandran S, Blumberg PM, Keck GE. Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues. Chembiochem 2018; 19:877-889. [PMID: 29424951 DOI: 10.1002/cbic.201700655] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Indexed: 11/10/2022]
Abstract
To investigate the cellular distribution of tumor-promoting vs. non-tumor-promoting bryostatin analogues, we synthesized fluorescently labeled variants of two bryostatin derivatives that have previously shown either phorbol ester-like or bryostatin-like biological activity in U937 leukemia cells. These new fluorescent analogues both displayed high affinity for protein kinase C (PKC) binding and retained the basic properties of the parent unlabeled compounds in U937 assays. The fluorescent compounds showed similar patterns of intracellular distribution in cells, however; this argues against an existing hypothesis that various patterns of intracellular distribution are responsible for differences in biological activity. Upon further characterization, the fluorescent compounds revealed a slow rate of cellular uptake; correspondingly, they showed reduced activity for cellular responses that were only transient upon treatment with phorbol ester or bryostatin 1.
Collapse
Affiliation(s)
- Thomas J Cummins
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Noemi Kedei
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Agnes Czikora
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Nancy E Lewin
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Sharon Kirk
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Mark E Petersen
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Kevin M McGowan
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Jin-Qiu Chen
- Collaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1044, Bethesda, MD, 20892, USA
| | - Xiaoling Luo
- Collaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1044, Bethesda, MD, 20892, USA
| | - Randall C Johnson
- Advanced Biomedical and Computational Sciences Biomedical Informatics, and Data Science (BIDS), Directorate Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research, Inc., Building 430, Miller Drive, Fort Detrick, Frederick, MD, 21702, USA
| | - Sarangan Ravichandran
- Advanced Biomedical and Computational Sciences Biomedical Informatics, and Data Science (BIDS), Directorate Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research, Inc., Building 430, Miller Drive, Fort Detrick, Frederick, MD, 21702, USA
| | - Peter M Blumberg
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Gary E Keck
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| |
Collapse
|
5
|
Abstract
The modified Julia reaction and acyl carbanion chemistry, especially reactions of 2-lithiated dithianes, have been investigated for the synthesis of intermediates that are the synthetic equivalents of the C11-C27 fragments of bryostatins. The modified Julia reaction using 2-benzothiazolylsulfones was found to be more useful for the formation of the C16-C17 double-bond than the classical Julia reaction using phenylsulfones, and bulky sulfones gave very good (E)-stereoselectivity. The alkylation of a dithiane monoxide that corresponded to a C19-acyl carbanion using (E)-1-bromobut-2-ene was efficient but the use of a more complex allylic bromide corresponding to the C20-C27 fragment of the bryostatins was unsuccessful, possibly due to competing elimination reactions. This meant that the use of C19 dithianes for the synthesis of 20-deoxybryostatins would have to involve the stepwise assembly of the C20-C27 fragment from simpler precursors. However, lithiated C19 dithianes gave good yields of adducts with aldehydes and conditions were developed for the stereoselective conversion of the major adducts into methoxyacetals that corresponded to the C17-C27 fragment of 20-oxygenated bryostatins. A convergent synthesis of the C11-C27 fragment of a 20-deoxybryostatin was subsequently achieved using a 2-benzothiazolylsulfone corresponding to the intact C17-C27 fragment.
Collapse
Affiliation(s)
- Anthony P Green
- The School of Chemistry, The University of Manchester, Manchester M13 9PL, UK.
| | | | | |
Collapse
|
6
|
Ketcham JM, Volchkov I, Chen TY, Blumberg PM, Kedei N, Lewin NE, Krische MJ. Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology. J Am Chem Soc 2016; 138:13415-13423. [PMID: 27676096 DOI: 10.1021/jacs.6b08695] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The synthesis and biological evaluation of chromane-containing bryostatin analogues WN-2-WN-7 and the previously reported salicylate-based analogue WN-8 are described. Analogues WN-2-WN-7 are prepared through convergent assembly of the chromane-containing fragment B-I with the "binding domain" fragment A-I or its C26-des-methyl congener, fragment A-II. The synthesis of fragment B-I features enantioselective double C-H allylation of 1,3-propanediol to form the C2-symmetric diol 3 and Heck cyclization of bromo-diene 5 to form the chromane core. The synthesis of salicylate WN-8 is accomplished through the union of fragments A-III and B-II. The highest binding affinities for PKCα are observed for the C26-des-methyl analogues WN-3 (Ki = 63.9 nM) and WN-7 (Ki = 63.1 nM). All analogues, WN-2-WN-8, inhibited growth of Toledo cells, with the most potent analogue being WN-7. This response, however, does not distinguish between phorbol ester-like and bryostatin-like behavior. In contrast, while many of the analogues contain a conserved C-ring in the binding domain and other features common to analogues with bryostatin-like properties, all analogues evaluated in the U937 proliferation and cell attachment assays displayed phorbol ester-like and/or toxic behavior, including WN-8, for which "bryostatin-like PKC modulatory activities" previously was suggested solely on the basis of PKC binding. These results underscore the importance of considering downstream biological effects, as tumor suppression cannot be inferred from potent PKC binding.
Collapse
Affiliation(s)
- John M Ketcham
- Department of Chemistry and Biochemistry, University of Texas at Austin , Austin, Texas 78712, United States
| | - Ivan Volchkov
- Department of Chemistry and Biochemistry, University of Texas at Austin , Austin, Texas 78712, United States
| | - Te-Yu Chen
- Department of Chemistry and Biochemistry, University of Texas at Austin , Austin, Texas 78712, United States
| | - Peter M Blumberg
- Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892-4255, United States
| | - Noemi Kedei
- Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892-4255, United States
| | - Nancy E Lewin
- Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892-4255, United States
| | - Michael J Krische
- Department of Chemistry and Biochemistry, University of Texas at Austin , Austin, Texas 78712, United States
| |
Collapse
|